The team developed a lung-targeted LNP to specifically deliver mRNA that encoded the normal Tsc2 gene into Tsc2-deficient TTJ cells for the treatment of lymphangioleiomyomatosis (LAM) caused by mutations in the Tsc2 gene. This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.